2017 Public Markets Overview

Topics

• 2017 Public Markets Overview

Topics:

• Fundraising environment generally for biotech companies
• Pros and cons of being a public company (including being the CEO of the public company)
  • Access to capital
  • Potential exit opportunities for investors, management and employees
  • Branding
• When to start thinking about public markets
  • Alternative fund-raising options available
  • Amount of time to prepare company infrastructure
  • Necessary/highly-desirable prerequisites that need to be in place to have a successful fund raising and ability to develop and maintain analyst coverage
• Options to consider (IPO, reverse merger, Form 10/direct registration)
  • The reasons to consider one path versus another
• Laying the groundwork
  • Retaining financial, legal and accounting advisors
  • Prerequisites to marketing (IPO), engaging with analysts (IPO, reverse merger) or finding investors (Form 10/direct registration)

Moderator

• Brian Goldstein – Partner, Choate, Hall & Stewart

Panelists

• Eugene Rozelman – Managing Director, Head of US Biotechnology and Specialty Pharma Investment Banking, Cannacord Genuity
• Jonathan Gertler, MD – Co-founder, Managing Partner and CEO, Back Bay Life Science Advisors
• Bill Marshall – President and CEO, Co-Founder and Director, miRagen Therapeutics
• Megan Gates – Partner, Mintz Levin